Oramed Pharmaceuticals
ORMP
47 hedge funds and large institutions have $16.3M invested in Oramed Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 16 reducing their positions, and 9 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less capital invested
Capital invested by funds: $16.6M → $16.3M (-$320K)
1.27% less ownership
Funds ownership: 19.03% → 17.75% (-1.3%)
10% less funds holding
Funds holding: 52 → 47 (-5)
56% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 9
56% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$193K |
| 2 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$138K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$56.9K |
| 4 |
Mariner
Overland Park,
Kansas
|
+$22.2K |
| 5 |
Wealth Enhancement Advisory Services
Plymouth,
Minnesota
|
+$11K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
-$456K |
| 2 |
PLC
Peapod Lane Capital
Bedford Hills,
New York
|
-$369K |
| 3 |
Two Sigma Investments
New York
|
-$138K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$114K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$86.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NEWAS
51
N.E.W. Advisory Services
De Pere,
Wisconsin
| – | -$40.4K | -18,900 | Closed |
|
|
PCM
52
Prelude Capital Management
New York
| – | -$28.8K | -13,435 | Closed |
|
53
Simplex Trading
Chicago,
Illinois
| – | -$16K | -7,244 | Closed |
|
54
Group One Trading
Chicago,
Illinois
| – | -$7.3K | -3,310 | Closed |
|
|
FHA
55
First Horizon Advisors
Memphis,
Tennessee
| – | -$3.75K | -1,750 | Closed |
|
|
TRCT
56
Tower Research Capital (TRC)
New York
| – | -$1.39K | -649 | Closed |
|
ORMP Hedge Fund Activity: Q2 2025 in Review
47 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q2 2025, worth a combined $16.3M — down 1.9% from $16.6M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of ORMP and 4 opened new positions — a net loss of 5 holders — while 16 trimmed existing stakes and 7 added.
The largest buyer was Citadel Advisors, adding an estimated $193K. The largest seller was Two Sigma Advisers, exiting entirely with an estimated $456K sold.
- 47 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q2 2025, down from 52 in Q1 2025.
- Funds reported $16.3M of Oramed Pharmaceuticals stock for Q2 2025, down 1.9% quarter-over-quarter.
- 4 funds opened new Oramed Pharmaceuticals positions in Q2 2025 and 9 closed out, a net change of -5 holders.
- The largest Oramed Pharmaceuticals buyer in Q2 2025 was Citadel Advisors, an estimated $193K added.
- The largest Oramed Pharmaceuticals seller in Q2 2025 was Two Sigma Advisers, an estimated $456K sold.
Based on aggregated 13F filings for Q2 2025.